
This file reports 2025 Medicare Advantage enrollment by parent organization. Each row lists the parent group, covered lives (MA only), market_share_pct, and cumulative_share_pct in rank order, along with source_url/source_title/source_date and last_verified fields indicating whether figures come from KFF’s July 2025 national update or CMS’s August 2025 Monthly Enrollment by Contract.
IV ketamine, medicare advantage, medicare, Spravato, ketamine therapy
IV ketamine, medicare advantage, medicare, Spravato, ketamine therapy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
